title: Lessons learned from 20 years of newborn screening for cystic fibrosis.
abstract: OBJECTIVE
  To compare three cystic fibrosis (CF) newborn screening strategies used in Victoria since 1989.
  
  
  METHODS
  Retrospective review of newborn screening and clinical records for people with CF born in Victoria between 1989 and 2008 to compare screening strategies: repeat immunoreactive trypsinogen (IRT) testing (IRT/IRT, 1989-1990), IRT and p.F508del mutation analysis (IRT/p.F508del, 1991-2006) and IRT with analysis of 12 CFTR mutations (IRT/12 mutations, 2007-2008).
  
  
  METHODS
  Total number of infants screened, people identified with CF (by screening or clinical diagnosis), number of CF-affected terminations of pregnancy, and number of carriers detected.
  
  
  RESULTS
  There were 420 people born with CF (live-birth prevalence, 1/3139; 95% CI, 1/2853-1/3462) and 78 CF-affected pregnancy terminations (overall prevalence, 1/2647; 95% CI, 1/2425-1/2896). Of the babies born with CF, 283 (67.4%) were detected by newborn screening alone, 61 (14.5%) had meconium ileus, 33 (7.9%) had a family history of CF, nine (2.1%) were diagnosed antenatally, and 34 (8.1%) were missed by screening (17 missed because IRT level was < 99th percentile, two with repeat IRT level not elevated, 14 without a screened CFTR mutation, and one with missing data). The sensitivities of the protocols were 86.6% for IRT/IRT, 89.9% for IRT/p.F508del, and 95.8% for IRT/12 mutations. Including 12 mutations in the analysis detected one patient who would otherwise have been missed and, had this protocol been implemented from 1989, it would have detected four others.
  
  
  CONCLUSIONS
  Most babies with CF without meconium ileus, a family history or antenatal diagnosis are detected by newborn screening. Despite improved sensitivity with the 12-mutation analysis, most infants detected would have been diagnosed using the IRT/p.F508del protocol.
authors.affiliation: Department of Respiratory Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC. john.massie@rch.org.au
authors.forename: R John H
authors.initials: RJ
authors.lastname: Massie
authors.forename: Lisette
authors.initials: L
authors.lastname: Curnow
authors.forename: Judith
authors.initials: J
authors.lastname: Glazner
authors.forename: David S
authors.initials: DS
authors.lastname: Armstrong
authors.forename: Ivan
authors.initials: I
authors.lastname: Francis
mesh_terms: D003550:Cystic Fibrosis / Q000175:diagnosis / Q000453:epidemiology* / Q000235:genetics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D004247:DNA / Q000032:analysis / Q000235:genetics; D004252:DNA Mutational Analysis; D005260:Female; D005500:Follow-Up Studies; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009154:Mutation; D015997:Neonatal Screening / Q000379:methods*; D011247:Pregnancy; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D013542:Sweat / Q000737:chemistry; D013997:Time Factors; D014362:Trypsinogen / Q000235:genetics; D014739:Victoria / Q000453:epidemiology
chemical_list: D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D014362:Trypsinogen; D004247:DNA